Efficacy and Safety of Disitamab Vedotin in Patients With Human Epidermal Growth Factor Receptor 2-Positive Locally Advanced or Metastatic Urothelial Carcinoma: A Combined Analysis of Two Phase II Clinical Trials.
Xinan ShengLin WangZhisong HeYanxia ShiHong LuoWeiqing HanXin YaoBenkang ShiZhenhua LiuChanglu HuZiling LiuHong-Qian GuoGuohua YuZhigang JiJian-Ming YingYun LingShiying YuYi HuJianming GuoJianmin FangAiping ZhouJun GuoPublished in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2023)
DV demonstrated a promising efficacy with a manageable safety profile in patients with HER2-positive locally advanced or metastatic UC who had progressed on at least one line of systemic chemotherapy.
Keyphrases
- locally advanced
- phase ii
- squamous cell carcinoma
- epidermal growth factor receptor
- clinical trial
- rectal cancer
- neoadjuvant chemotherapy
- open label
- tyrosine kinase
- phase ii study
- radiation therapy
- advanced non small cell lung cancer
- small cell lung cancer
- endothelial cells
- phase iii
- placebo controlled
- induced pluripotent stem cells
- hodgkin lymphoma
- double blind
- pluripotent stem cells
- lymph node